Changes in Hong Kong stocks | Kefu Healthcare (01187) rose more than 10%, respiratory support became the main engine of growth, AI and ecological cooperation accelerated implementation

The Zhitong Finance App learned that Corfu Healthcare (01187) rose by more than 10%. As of press release, it had risen 10.4% to HK$30.16, with a turnover of HK$474.47 million.

According to news, in the first half of this year, Corfu Healthcare achieved operating income of 2,072 billion yuan, an increase of 38.51% year on year; net profit to mother was 202 million yuan, up 20.84% year on year; and realized deducted non-net profit of 173 million yuan, an increase of 26.73% year on year. In the first half of the year, the company's top five single product revenue increased 50% year over year. By sector, respiratory support revenue was 267 million yuan, an increase of 166.90% over the previous year, and sales of self-developed ventilators in the second quarter exceeded 100 million yuan.

Zhongtai Securities previously stated that the company set up an artificial intelligence research institute to promote the development of large models of Corfu, and completed engineering verification of end-side intelligent algorithms using ventilators as the first application scenario; the next-generation AI ventilator C11 was officially launched. The CGM independently developed by the participating company Shenzhen Kefu Biotech has obtained registration certificates for three types of medical devices, and two blood sugar monitoring systems have obtained EU IVDR certification. The company and Tencent Teana Laboratory launched the bone conduction hearing aid X5. The first batch of 17 products in 5 categories was connected to Hongmeng Ecology, and a production line for products such as blood pressure monitors, blood sugar meters, oximeters, and thermometers under the Royal Philips brand has been built.